HRGN — Harvard Apparatus Regenerative Technology Income Statement
0.000.00%
- $31.33m
- $30.61m
- $0.43m
Annual income statement for Harvard Apparatus Regenerative Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.103 | 0.43 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.079 | 0.16 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.33 | 8.23 | 6.15 | 9.09 | 8.16 |
| Operating Profit | -5.33 | -8.23 | -6.15 | -8.99 | -7.73 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
| Net Income After Taxes | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.87 | -7.98 | -6.25 | -9.02 | -7.73 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.553 | -0.833 | -0.551 | -0.67 | -0.523 |